Patents by Inventor David Edward Ehmann

David Edward Ehmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20230078513
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 16, 2023
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20200317667
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 10730874
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: August 4, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20190284182
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 19, 2019
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard